# Cardiac Myosin-Binding Protein C (cMyC) as a Novel Biomarker for Early Diagnosis of Myocardial Infarction: A Brief Review

## TL;DR

This review explores cMyC as a new biomarker for early detection of heart attacks, potentially offering faster diagnosis than traditional markers.

## Contribution

The paper highlights cMyC's potential as a novel biomarker for early myocardial infarction diagnosis due to its rapid release and clearance.

## Key findings

- cMyC rises and falls faster than high-sensitivity troponins, enabling earlier MI detection.
- cMyC may improve early decision-making in emergency settings compared to conventional biomarkers.
- Further large-scale studies are needed to confirm cMyC's clinical utility and integration into diagnostic pathways.

## Abstract

This article is a narrative review summarizing current evidence on the diagnostic value of cardiac myosin-binding protein C (cMyC) compared with conventional cardiac biomarkers. Cardiac myosin-binding protein C (cMyC) has emerged as a novel biomarker with potential advantages over conventional troponins for the early diagnosis of myocardial infarction (MI). Its rapid release and clearance kinetics may provide opportunities for improved risk stratification and patient management. This review explores the diagnostic potential of cMyC in the detection of MI and considers its possible role in post-infarction monitoring. A systematic literature search was conducted in PubMed, Embase, and the Cochrane Library from inception to September 2025 using the terms “cardiac myosin-binding protein C,” “cMyC,” “myocardial infarction,” “acute coronary syndrome,” and “biomarker.” Studies were included if they investigated cMyC kinetics, diagnostic accuracy, or its clinical application in patients with suspected or confirmed MI. Original clinical trials, observational studies, and translational research articles published in English were eligible. Review articles, editorials, case reports, and non-English publications were excluded. Evidence suggests that cMyC rises and falls more rapidly than high-sensitivity troponins, enabling earlier identification of MI and offering value for short-term monitoring following cardiac events. Compared to troponins, cMyC may improve early decision-making in the emergency setting. However, current research remains limited, and further studies are needed. cMyC is a promising biomarker for early MI diagnosis and hospital-based follow-up. Future large-scale, multicenter studies are essential to confirm its clinical utility and establish its role in existing diagnostic pathways.